In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mark Gelfand And Howard Levin, The Folks Who Brought You Renal Denervation

Executive Summary

Renal denervation is arguably the hottest new device technology to come along in years, with applications in a variety of chronic diseases including hypertension and diabetes, to name just two. Yet just over a decade ago, most people laughed off the concept, and they might still be laughing were it not for the efforts of a novel device development company called Coridea.

You may also be interested in...



The New Math Of Ortho Innovation – An Interview With Zimmer CEO David Dvorak

After emerging from the DOJ settlements, the leading pure-play orthopedics company is emphasizing – and redefining – innovation to drive growth. Zimmer CEO David Dvorak talks to IN VIVO about his company’s commitment to innovation, and how the very notion of innovation is changing.

Medtech Innovation From An Industrial Perspective: An Interview With GE Healthcare’s John Dineen

Because the GE brand is so ubiquitous, visible on everything from household appliances to airplane engines, it’s easy to assume a familiarity with GE and, in particular, with what its health care business is all about. But this interview with John Dineen, President and CEO of GE Healthcare and GE Medical Systems Information Technologies Inc. makes clear that GE’s world view is anything but familiar and stands in striking contrast to that of most other medical technology companies.

Covidien 2.0 – A Conversation With Joe Almeida

Covidien President and CEO Joe Almeida is positioning the company to continue its dynamic growth. Having run up an impressive track record over the past several years, where will – where can-- Covidien go from here?

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL1122113

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel